ClinicalTrials.gg
CompletedNCT01347580ATLANTICUpdated Jul 22, 2015Results posted

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

A Phase 4 interventional study of Ticagrelor and Placebo in Myocardial Infarction and Segment Elevation Myocardial Infarction (STEMI), sponsored by AstraZeneca. Completed at 101 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-22.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,875
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing ticagrelor in Myocardial Infarction — 3 open to participants now, 3 under way, 1 of them phase 3. Ticagrelor · Myocardial Infarction.

Enrollment
8th of 36
1,875 · median 132
Started
2011
the only one that year
Phase 4
20 of 36
2 open now
Registered
5th of 36
by date
Lead sponsor
6 of 36
AstraZeneca

Among the 36 studies testing ticagrelor in Myocardial Infarction, this one is the 8th largest by enrollment, is the only one that started in 2011, is one of 20 in phase 4, and was the 5th registered.

Myocardial Infarction

2,274 studies on the registry are indexed under Myocardial Infarction; 375 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

3 of the 36 studies testing ticagrelor in Myocardial Infarction are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing ticagrelor in Myocardial Infarction, or all of them as a file.
02

Study summary

The aim of this study is to determine whether initiation of ticagrelor as early as in the ambulance setting leads to a rapid reperfusion of the infarct-related artery therefore facilitating the Percutaneous Coronary Intervention (PCI) and optimizing the outcome for the patient.

The study will assess the efficacy and safety of pre-hospital compared to in-hospital administration of ticagrelor in co-administration with aspirin, on restoring the blood flow in the occluded heart artery and improving the myocardial perfusion in patients suffering from myocardial infarction and planned to have a PCI. Patients can be randomised in either one of the 2 arms:

re-hospital ticagrelor arm: Patients will receive a loading dose of 180 mg ticagrelor for the pre-hospital administration and placebo for in-hospital administration.

or In-hospital ticagrelor arm: Patients will receive a placebo for pre-hospital administration and 180 mg ticagrelor loading dose for in-hospital administration.

Patients are initially managed by ambulance physician/personnel in pre hospital settings. They are then transferred into a Catheterization room to undergo a PCI.

After the administration of the loading dose of ticagrelor (double blind), patients will continue on ticagrelor 90 mg bid and be followed in study for 30 days post randomisation.

03

Conditions studied

  • Myocardial Infarction
  • Segment Elevation Myocardial Infarction (STEMI)

Keywords

  • Heart attack
  • heart disease
  • cardiovascular disease
  • stroke
  • reperfusion
  • pre hospital settings
  • ticagrelor
  • Percutaneous Coronary Intervention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women must not be of (1 year or surgically sterile).
  • Symptoms of acute MI of more than 30 min but less than 6 hours
  • New persistent ST-segment elevation ≥ 1 mm in two or more contiguous (ECG) leads.

Exclusion criteria

Exclusion Criteria:

  • Expected time to 1st PCI balloon inflation in the hospital, from the qualifying is more than 120 minutes
  • to ticagrelor (refer to SmPC)
  • Concomitant medication that may increase the risk of bleeding [e.g non steroidal anti-inflammatory drugs (NSAIDs), oral anticoagulant and / or fibrinolytics, planned or administered 24 hours before randomization]
  • Any of the following conditions in the absence of a functioning implanted pacemaker: known SSS, second or third degree AVB, or documented syncope of suspected bradycardic origin.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,875 participants (actual)

Study arms

  • Experimental
    Ticagrelor

    Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.

    Drug: Ticagrelor

  • Experimental
    Placebo

    Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.

    Drug: Placebo

Interventions

  • Oral Ticagrelor loading dose (180 mg) followed by matching placebo

  • DrugPlacebo

    Placebo followed by oral Ticagrelor loading dose (180 mg)

06

What researchers measure

Primary outcomes

  1. Thrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint)

    (TIMI) flow grade classification is used to assess coronary blood flow in acute coronary syndromes. grade 0:no reperfusion, grade 1: penetration without perfusion, grade 2: Partial reperfusion, grade 3: complete perfusion.

    Time frame: At initial angiography, pre PCI

  2. ST-segment Elevation Resolution Pre PCI ≥70% (Co-primary Endpoint)

    ST segment elevation resolution is the mean ST elevation pre-hospital minus the mean STelevation pre-PCI divided by the mean ST elevation pre-hospital. It is expressed as a percentage and split in 2 categories , complete (≥70%) versus incomplete (\<70%) resolution.

    Time frame: Between baseline and PCI

Secondary outcomes

  1. 1st Composite Clinical Endpoint

    death/MI/stroke/urgent revascularization/stent thrombosis. Adjudicated events except death

    Time frame: during the 30 days of treatment

  2. 2nd Composite Clinical Endpoint

    Death/MI/urgent revascularization. Adjudicated events except death

    Time frame: within 30 days of study

  3. Definite Stent Thrombosis

    Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. It is an adjudicated endpoint

    Time frame: during 30 days of treatment

  4. TIMI Flow Grade 3 Post -PCI

    TIMI) flow grade 3 is complete perfusion post-PCI.

    Time frame: at coroangiography post-PCI

  5. ST Segment Elevation Resolution Post-PCI >= 70%

    ST segment elevation resolution post PCI \>=70% is defined as complete resolution

    Time frame: Between baseline and ECG 60 mn post-PCI

  6. Thrombotic Bail-out With GPIIb/IIIa Inhibitors at Initial PCI

    Glycoprotein (GP) IIb/IIIa inhibitors are often used as a rescue or bailout therapy to manage complications arising during percutaneous coronary intervention.

    Time frame: during PCI

  7. Major Bleeds Within 48 Hours

    non CABG related bleeds, (PLATO definition) include Life threatening and other major bleeds

    Time frame: within 48 hours of first dose

  8. Minor and Major Bleedings Within 48 Hours

    non CABG related bleeds (PLATO definition)

    Time frame: within 48 hours of first dose

  9. Major Bleeds After 48 Hours

    non CABG related bleeds (PLATO definition) include life threatening and other major bleedings

    Time frame: after 48hours post-first dose

  10. Minor and Major Bleeds After 48 Hours

    non CABG related bleeds (PLATO definition)

    Time frame: after 48 hours post first dose

07

Results

Posted Feb 11, 2015
Limitations and caveats
This urgent setting study included 8.6% of patients with symptoms of MI in ambulance but having finally not a STEMI diagnosis in cathlab. No prespecified hypothesis and procedure for adjustment was made on secondary endpoints.

Participant flow

Patients were randomized in pre-hospital settings at 102 Emergency Medical Services between September 2011 and October 2013. 1875 patients were recruited in the study, 1862 consented patients were randomized.

Participant flow — Overall Study
MilestonePre-hospital TicagrelorIn-hospital Ticagrelor
Started909953
Modified intent to treat population906952
Safety population908950
Completed844897
Not completed6556
Withdrew: Withdrawal by subject1323
Withdrew: Death3019
Withdrew: Protocol violation107
Withdrew: Lost to follow-up31
Withdrew: Had other reason96

Outcome measures

PrimaryThrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint)

(TIMI) flow grade classification is used to assess coronary blood flow in acute coronary syndromes. grade 0:no reperfusion, grade 1: penetration without perfusion, grade 2: Partial reperfusion, grade 3: complete perfusion.

Time frame:
At initial angiography, pre PCI
Reported as:
Number · patients
Thrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint)
patientsPre-hospital TicagrelorIn-hospital Ticagrelor
Thrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint)143145
Statistical analysis
  • Pre-hospital Ticagrelor vs In-hospital Ticagrelor · Regression, Logistic · p = 0.8214 (pvalue at 0.025 , adjusted for multiple comparisons) · Odds ratio (or): 1.030 · 95% CI 0.799 to 1.327
PrimaryST-segment Elevation Resolution Pre PCI ≥70% (Co-primary Endpoint)

ST segment elevation resolution is the mean ST elevation pre-hospital minus the mean STelevation pre-PCI divided by the mean ST elevation pre-hospital. It is expressed as a percentage and split in 2 categories , complete (≥70%) versus incomplete (\<70%) resolution.

Time frame:
Between baseline and PCI
Reported as:
Number · patients
ST-segment Elevation Resolution Pre PCI ≥70% (Co-primary Endpoint)
patientsPre-hospital TicagrelorIn-hospital Ticagrelor
ST-segment Elevation Resolution Pre PCI ≥70% (Co-primary Endpoint)102102
Statistical analysis
  • Pre-hospital Ticagrelor vs In-hospital Ticagrelor · Regression, Logistic · p = 0.6322 (P value at 0.025 adjusted for multiple comparisons) · Odds ratio (or): 1.074 · 95% CI 0.801 to 1.441
Secondary1st Composite Clinical Endpoint

death/MI/stroke/urgent revascularization/stent thrombosis. Adjudicated events except death

Time frame:
during the 30 days of treatment
Reported as:
Number · patients
1st Composite Clinical Endpoint
patientsPre-hospital TicagrelorIn-hospital Ticagrelor
1st Composite Clinical Endpoint4142
Statistical analysis
  • Pre-hospital Ticagrelor vs In-hospital Ticagrelor · Regression, Logistic · p = 0.9056 · Odds ratio (or): 1.027 · 95% CI 0.661 to 1.595
Secondary2nd Composite Clinical Endpoint

Death/MI/urgent revascularization. Adjudicated events except death

Time frame:
within 30 days of study
Reported as:
Number · patients
2nd Composite Clinical Endpoint
patientsPre-hospital TicagrelorIn-hospital Ticagrelor
2nd Composite Clinical Endpoint3934
Statistical analysis
  • Pre-hospital Ticagrelor vs In-hospital Ticagrelor · Regression, Logistic · p = 0.4168 · Odds ratio (or): 1.215 · 95% CI 0.760 to 1.942
SecondaryDefinite Stent Thrombosis

Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. It is an adjudicated endpoint

Time frame:
during 30 days of treatment
Reported as:
Number · patients
Definite Stent Thrombosis
patientsPre-hospital TicagrelorIn-hospital Ticagrelor
Definite Stent Thrombosis211
Statistical analysis
  • Pre-hospital Ticagrelor vs In-hospital Ticagrelor · Regression, Logistic · p = 0.0307 · Odds ratio (or): 0.189 · 95% CI 0.042 to 0.856
SecondaryTIMI Flow Grade 3 Post -PCI

TIMI) flow grade 3 is complete perfusion post-PCI.

Time frame:
at coroangiography post-PCI
Reported as:
Number · patients
TIMI Flow Grade 3 Post -PCI
patientsPre-hospital TicagrelorIn-hospital Ticagrelor
TIMI Flow Grade 3 Post -PCI625630
Statistical analysis
  • Pre-hospital Ticagrelor vs In-hospital Ticagrelor · Regression, Logistic · p = 0.344 · Odds ratio (or): 1.132 · 95% CI 0.876 to 1.462
SecondaryST Segment Elevation Resolution Post-PCI >= 70%

ST segment elevation resolution post PCI \>=70% is defined as complete resolution

Time frame:
Between baseline and ECG 60 mn post-PCI
Reported as:
Number · patients
ST Segment Elevation Resolution Post-PCI >= 70%
patientsPre-hospital TicagrelorIn-hospital Ticagrelor
ST Segment Elevation Resolution Post-PCI >= 70%410390
Statistical analysis
  • Pre-hospital Ticagrelor · Regression, Logistic · p = 0.0547 · Odds ratio (or): 1.225 · 95% CI 0.996 to 1.506
SecondaryThrombotic Bail-out With GPIIb/IIIa Inhibitors at Initial PCI

Glycoprotein (GP) IIb/IIIa inhibitors are often used as a rescue or bailout therapy to manage complications arising during percutaneous coronary intervention.

Time frame:
during PCI
Reported as:
Number · patients
Thrombotic Bail-out With GPIIb/IIIa Inhibitors at Initial PCI
patientsPre-hospital TicagrelorIn-hospital Ticagrelor
Thrombotic Bail-out With GPIIb/IIIa Inhibitors at Initial PCI78100
Statistical analysis
  • Pre-hospital Ticagrelor vs In-hospital Ticagrelor · Regression, Logistic · p = 0.1660 · Odds ratio (or): 0.803 · 95% CI 0.588 to 1.096
SecondaryMajor Bleeds Within 48 Hours

non CABG related bleeds, (PLATO definition) include Life threatening and other major bleeds

Time frame:
within 48 hours of first dose
Reported as:
Number · patients
Major Bleeds Within 48 Hours
patientsPre-hospital TicagrelorIn-hospital Ticagrelor
Major Bleeds Within 48 Hours1615
SecondaryMinor and Major Bleedings Within 48 Hours

non CABG related bleeds (PLATO definition)

Time frame:
within 48 hours of first dose
Reported as:
Number · patients
Minor and Major Bleedings Within 48 Hours
patientsPre-hospital TicagrelorIn-hospital Ticagrelor
Minor and Major Bleedings Within 48 Hours2424
SecondaryMajor Bleeds After 48 Hours

non CABG related bleeds (PLATO definition) include life threatening and other major bleedings

Time frame:
after 48hours post-first dose
Reported as:
Number · patients
Major Bleeds After 48 Hours
patientsPre-hospital TicagrelorIn-hospital Ticagrelor
Major Bleeds After 48 Hours1111
SecondaryMinor and Major Bleeds After 48 Hours

non CABG related bleeds (PLATO definition)

Time frame:
after 48 hours post first dose
Reported as:
Number · patients
Minor and Major Bleeds After 48 Hours
patientsPre-hospital TicagrelorIn-hospital Ticagrelor
Minor and Major Bleeds After 48 Hours1816

Adverse events

Collected over within 30 days of study. Non-serious events are listed at a 3.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ticagrelor In-Hosp—143/950 (15.1%)529/950 (55.7%)
Ticagrelor Pre-Hosp—140/908 (15.4%)469/908 (51.7%)
Most frequent serious events
Showing 10 of 141
Most frequent serious events
EventTicagrelor In-HospTicagrelor Pre-Hosp
VENTRICULAR FIBRILLATIONCardiac disorders30/95023/908
CARDIOGENIC SHOCKCardiac disorders16/95017/908
CARDIAC ARRESTCardiac disorders7/95011/908
CARDIAC FAILURECardiac disorders7/9507/908
VENTRICULAR TACHYCARDIACardiac disorders7/9506/908
NON-CARDIAC CHEST PAINGeneral disorders5/9504/908
ATRIAL FIBRILLATIONCardiac disorders2/9504/908
PULMONARY OEDEMARespiratory, thoracic and mediastinal disorders1/9504/908
INTRACARDIAC THROMBUSCardiac disorders4/9502/908
PERICARDIAL EFFUSIONCardiac disorders4/9500/908
Most frequent other events
Showing 10 of 12
Most frequent other events
EventTicagrelor In-HospTicagrelor Pre-Hosp
DyspnoeaGastrointestinal disorders86/95062/908
Ventricular tachycardiaCardiac disorders81/95079/908
Non cardiac chest painGeneral disorders52/95042/908
NauseaGastrointestinal disorders49/95041/908
HypotensionVascular disorders30/95044/908
VomitingGastrointestinal disorders40/95034/908
Atrial fibrillationCardiac disorders38/95030/908
Ventricular fibrillationCardiac disorders37/95032/908
Cardiac failureCardiac disorders33/95030/908
HeadacheNervous system disorders31/95019/908

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pre-hospital TicagrelorIn-hospital TicagrelorTotal
Years60.6 ± 12.3861.0 ± 12.4960.8 ± 12.43
Sex: Female, Male
Sex: Female, Male(Participants)Pre-hospital TicagrelorIn-hospital TicagrelorTotal
Female173196369
Male7367571493
Diabetes mellitus
Diabetes mellitus(patients)Pre-hospital TicagrelorIn-hospital TicagrelorTotal
yes115138253
no/unknown7948151609
TIMI risk score
TIMI risk score(patients)Pre-hospital TicagrelorIn-hospital TicagrelorTotal
0-25525731125
3-6337365702
>6201535
Killip class
Killip class(patients)Pre-hospital TicagrelorIn-hospital TicagrelorTotal
I8198621681
II, III, IV514394
unknown394887
First medical contact
First medical contact(patients)Pre-hospital TicagrelorIn-hospital TicagrelorTotal
in ambulance6897231412
in emergency department220230450
PCI
PCI(Patients)Pre-hospital TicagrelorIn-hospital TicagrelorTotal
yes8008301630
no109123232
type of PCI
type of PCI(patients)Pre-hospital TicagrelorIn-hospital TicagrelorTotal
with stent7607761536
without stent405494

1 further baseline measures are reported on the registry.

08

Study locations

101 sites
  • Research Site
    Algiers, Algeria
  • Research Site
    Blida, Algeria
  • Research Site
    Herston, Australia
  • Research Site
    Southport, Australia
  • Research Site
    Woolloongabba, Australia
  • Research Site
    Graz, Austria
  • Research Site
    Innsbruck, Austria
  • Research Site
    Wien, Austria
  • Research Site
    Halifax, Nova Scotia, Canada
  • Research Site
    Newmarket, Ontario, Canada
  • Research Site
    Scarborough, Ontario, Canada
  • Research Site
    Regina, Saskatchewan, Canada
  • Research Site
    Aalborg, Denmark
  • Research Site
    Odense C, Denmark
  • Research Site
    Århus, Denmark
  • Research Site
    Aubervilliers, France
  • Research Site
    Besançon, France
  • Research Site
    Boulogne Billancourt, France
  • Research Site
    Bourges, France
  • Research Site
    Bron, France
  • Research Site
    Chateauroux, France
  • Research Site
    Corbeil Essonnes Cedex, France
  • Research Site
    Creteil, France
  • Research Site
    Dijon, France
  • Research Site
    LAGNY SUR MARNE cedex, France
  • Research Site
    Le Chesnay, France
  • Research Site
    Le Coudray, France
  • Research Site
    Lyon Cedex 04, France
  • Research Site
    Lyon, France
  • Research Site
    MARSEILLE cedex 15, France
  • Research Site
    Marseille, France
  • Research Site
    Massy, France
  • Research Site
    Melun, France
  • Research Site
    Montauban, France
  • Research Site
    Montfermeil, France
  • Research Site
    MONTREUIL Cedex, France
  • Research Site
    Neuilly Sur Seine, France
  • Research Site
    Nimes, France
  • Research Site
    Paris Cedex 13, France
  • Research Site
    PARIS Cedex 15, France
  • Research Site
    Paris, France
  • Research Site
    PESSAC Cedex, France
  • Research Site
    Quincy sous Sénart, France
  • Research Site
    Rouen Cedex, France
  • Research Site
    Strasbourg, France
  • Research Site
    TOURS Cedex 9, France
  • Research Site
    TOURS cedex, France
  • Research Site
    VANNES cedex, France
  • Research Site
    Bad Friedrichshall, Germany
  • Research Site
    Bad Nauheim, Germany
  • Research Site
    Darmstadt, Germany
  • Research Site
    Esslingen, Germany
  • Research Site
    Freiburg, Germany
  • Research Site
    Gießen, Germany
  • Research Site
    Hannover, Germany
  • Research Site
    Ludwigshafen, Germany
  • Research Site
    Lüdenscheid, Germany
  • Research Site
    Mainz, Germany
  • Research Site
    Merseburg, Germany
  • Research Site
    Wuppertal, Germany
  • Research Site
    Budapest, Hungary
  • Research Site
    Debrecen, Hungary
  • Research Site
    Pécs, Hungary
  • Research Site
    Szeged, Hungary
  • Research Site
    Arezzo, Italy
  • Research Site
    Ascoli Piceno, Italy
  • Research Site
    Cona, Italy
  • Research Site
    Forlì, Italy
  • Research Site
    Genova, Italy
  • Research Site
    Grosseto, Italy
  • Research Site
    Massa, Italy
  • Research Site
    Seriate, Italy
  • Research Site
    Siena, Italy
  • Research Site
    Alkmaar, Netherlands
  • Research Site
    Arnhem, Netherlands
  • Research Site
    Den Bosch, Netherlands
  • Research Site
    Terneuzen, Netherlands
  • Research Site
    A Coruña, Spain
  • Research Site
    Alicante, Spain
  • Research Site
    Badalona, Spain
  • Research Site
    Barcelona, Spain
  • Research Site
    Hospitalet de Llobregat(Barcel, Spain
  • Research Site
    Madrid, Spain
  • Research Site
    Málaga, Spain
  • Research Site
    Santiago(A Coruña), Spain
  • Research Site
    Sevilla, Spain
  • Research Site
    Vigo(Pontevedra), Spain
  • Research Site
    Gävle, Sweden
  • Research Site
    Linköping, Sweden
  • Research Site
    Uppsala, Sweden
  • Research Site
    Örebro, Sweden
  • Research Site
    Ashford, United Kingdom
  • Research Site
    Belfast, United Kingdom
  • Research Site
    Cambridge, United Kingdom
  • Research Site
    Coventry, United Kingdom
  • Research Site
    Eastbourne, United Kingdom
  • Research Site
    Hastings, United Kingdom
  • Research Site
    Middlesborough, United Kingdom
  • Research Site
    Newcastle-Upon-Tyne, United Kingdom
  • Research Site
    Norwich, United Kingdom

Showing the first 100 of 101 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Montalescot G, van 't Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Stibbe O, Ecollan P, Heutz WM, Swahn E, Collet JP, Willems FF, Baradat C, Licour M, Tsatsaris A, Vicaut E, Hamm CW; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014 Sep 11;371(11):1016-27. doi: 10.1056/NEJMoa1407024. Epub 2014 Sep 1. PubMed 25175921 ↗
  • Lapostolle F, Van't Hof AW, Hamm CW, Stibbe O, Ecollan P, Collet JP, Silvain J, Lassen JF, Heutz WMJM, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Ten Berg J, Zeymer U, Licour M, Tsatsaris A, Montalescot G; ATLANTIC Investigators. Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. Am J Cardiovasc Drugs. 2019 Apr;19(2):173-183. doi: 10.1007/s40256-018-0305-0. PubMed 30353444 ↗
  • Fabris E, Van't Hof A, Hamm CW, Lapostolle F, Lassen JF, Goodman SG, Ten Berg JM, Bolognese L, Cequier A, Chettibi M, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Cantor WJ, Kerneis M, Diallo A, Vicaut E, Montalescot G; ATLANTIC investigators. Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trial. Catheter Cardiovasc Interv. 2019 Jun 1;93(7):E369-E377. doi: 10.1002/ccd.27921. Epub 2018 Oct 9. PubMed 30302940 ↗
  • Bagai A, Goodman SG, Cantor WJ, Vicaut E, Bolognese L, Cequier A, Chettibi M, Hammett CJ, Huber K, Janzon M, Lapostolle F, Lassen JF, Merkely B, Storey RF, Ten Berg JM, Zeymer U, Diallo A, Hamm CW, Tsatsaris A, El Khoury J, Van't Hof AW, Montalescot G. Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study. Am Heart J. 2018 Feb;196:56-64. doi: 10.1016/j.ahj.2017.10.021. Epub 2017 Nov 4. PubMed 29421015 ↗
  • Kilic S, Fabris E, Van't Hof AWJ, Hamm CW, Lapostolle F, Lassen JF, Tsatsaris A, Diallo A, Vicaut E, Montalescot G; ATLANTIC Investigators. Thrombus aspiration and prehospital ticagrelor administration in ST-elevation myocardial infarction: Findings from the ATLANTIC trial. Am Heart J. 2018 Feb;196:1-8. doi: 10.1016/j.ahj.2017.09.018. Epub 2017 Oct 3. PubMed 29421001 ↗
  • Venetsanos D, Sederholm Lawesson S, Alfredsson J, Janzon M, Cequier A, Chettibi M, Goodman SG, Van't Hof AW, Montalescot G, Swahn E. Association between gender and short-term outcome in patients with ST elevation myocardial infraction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis. BMJ Open. 2017 Sep 21;7(9):e015241. doi: 10.1136/bmjopen-2016-015241. PubMed 28939567 ↗
  • Cayla G, Lapostolle F, Ecollan P, Stibbe O, Benezet JF, Henry P, Hammett CJ, Lassen JF, Storey RF, Ten Berg JM, Hamm CW, Van't Hof AW, Montalescot G; ACTION study group. Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC population. Int J Cardiol. 2017 Oct 1;244:49-53. doi: 10.1016/j.ijcard.2017.06.009. Epub 2017 Jun 9. PubMed 28622941 ↗
  • Lupi A, Schaffer A, Lazzero M, Tessitori M, De Martino L, Rognoni A, Bongo AS, Porto I. Pre-hospital ticagrelor in patients with ST-segment elevation myocardial infarction with long transport time to primary PCI facility. Cardiovasc Revasc Med. 2016 Dec;17(8):528-534. doi: 10.1016/j.carrev.2016.08.005. Epub 2016 Aug 20. PubMed 27666002 ↗
  • Silvain J, Storey RF, Cayla G, Esteve JB, Dillinger JG, Rousseau H, Tsatsaris A, Baradat C, Salhi N, Hamm CW, Lapostolle F, Lassen JF, Collet JP, Ten Berg JM, Van't Hof AW, Montalescot G. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb Haemost. 2016 Aug 1;116(2):369-78. doi: 10.1160/TH15-12-0944. Epub 2015 May 19. PubMed 27196998 ↗
  • Montalescot G, van 't Hof AW, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Collet JP, Goodman SG, Hammett CJ, Huber K, Janzon M, Lapostolle F, Lassen JF, Licour M, Merkely B, Salhi N, Silvain J, Storey RF, Ten Berg JM, Tsatsaris A, Zeymer U, Vicaut E, Hamm CW; ATLANTIC Investigators. Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H(2)(4) Analysis. JACC Cardiovasc Interv. 2016 Apr 11;9(7):646-56. doi: 10.1016/j.jcin.2015.12.024. Epub 2016 Mar 5. PubMed 26952907 ↗
  • Montalescot G, Lassen JF, Hamm CW, Lapostolle F, Silvain J, ten Berg JM, Cantor WJ, Goodman SG, Licour M, Tsatsaris A, van't Hof AW. Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study. Am Heart J. 2013 Apr;165(4):515-22. doi: 10.1016/j.ahj.2012.12.015. Epub 2013 Feb 13. PubMed 23537967 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2011
First posted
May 4, 2011
Start
Sep 2011
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results first posted
Feb 11, 2015
Last update
Jul 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01347580
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 4, 2011
Start date
Sep 2011
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Feb 11, 2015
Last update
Jul 22, 2015

Study contacts

Dr Judith Hsia, MD
study director · AstraZeneca
Pr Gilles Montalescot
principal investigator · Pitie Salpetriere Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion